Cardiovascular manifestations of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome)

被引:36
作者
Golda, Adam [2 ]
Jurecka, Agnieszka [1 ,3 ]
Tylki-Szymanska, Anna [1 ]
机构
[1] Childrens Mem Hlth Inst, Metab Dis Clin, PL-04730 Warsaw, Poland
[2] Silesian Ctr Heart Dis, Dept Cardiol Congenital Heart Dis & Electrotherap, Zabrze, Poland
[3] Univ Gdansk, Dept Mol Biol, PL-80952 Gdansk, Poland
关键词
Mucopolysaccharidosis type VI; Maroteaux-Lamy syndrome; Valvular disease; Cardiomyopathy; Heart failure; Cardiac aneurysm; RETROVIRALLY MEDIATED OVEREXPRESSION; TRANSFEMORAL PACEMAKER IMPLANTATION; ELASTIN-BINDING PROTEIN; FORMATION IN-VITRO; ENDOCARDIAL FIBROELASTOSIS; IMPAIRED ELASTOGENESIS; TROPOELASTIN SYNTHESIS; HURLER-DISEASE; VERSICAN V3; FIBROBLASTS;
D O I
10.1016/j.ijcard.2011.06.097
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of the article is to gather and summarize the published data about the incidence, course of illness, treatment possibilities and complications of cardiovascular disorders in patients with mucopolysaccharidosis type VI (MPS VI) also known as Maroteaux-Lamy syndrome. MPS VI is a lysosomal storage disorder caused by deficient activity of N-acetylogalactosamine-4-sulfatase leading to progressive intracellular accumulation of glycosaminoglycans. The relatively low birth prevalence ranging from 1 in 43,000 to1 in 1.5 million births mirrors the limited descriptions of the cardiovascular disorders in the medical literature. Patients with MPS VI can be specifically treated with enzyme replacement therapy. Extra-cardiac features include growth retardation, coarse facial features, stiff joints, skeletal malformations (dysostosis multiplex), respiratory problems, corneal clouding, and hepatosplenomegaly. The clinical presentation varies considerably, however the development of heart disease and cardiac dysfunction is a serious problem in the majority of patients. The most characteristic cardiac presentation is valvular disease, while other MPS VI patients also develop cardiomyopathy, fibroelastosis, pulmonary hypertension, cardiac conduction system disorders and other complications. There are also reports on acute heart failure. Early cardiovascular manifestation may escape detection since joint stiffness or skeletal malformations limit maximal exercise levels and respiratory system involvement may mask the underlining cardiac insufficiency. A correct and timely diagnosis offers the possibility of disease-specific treatment leading to sustained clinical benefits for cardiac and non-cardiac MPS VI manifestations. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:6 / 11
页数:6
相关论文
共 43 条
  • [1] [Anonymous], ANN ESTIMATES POPULA
  • [2] Clinical and biochemical study of 28 patients with mucopolysaccharidosis type VI
    Azevedo, ACMM
    Schwartz, IV
    Kalakun, L
    Brustolin, S
    Burin, MG
    Beheregaray, APC
    Leistner, S
    Giugliani, C
    Rosa, M
    Barrios, P
    Marinho, D
    Esteves, P
    Valadares, E
    Boy, R
    Horovitz, D
    Mabe, P
    da Silva, LCS
    de Souza, ICN
    Ribeiro, M
    Martins, AM
    Palhares, D
    Kim, CA
    Giugliani, R
    [J]. CLINICAL GENETICS, 2004, 66 (03) : 208 - 213
  • [3] Cumulative incidence rates of the mucopolysaccharidoses in Germany
    Baehner, F
    Schmiedeskamp, C
    Krummenauer, F
    Miebach, E
    Bajbouj, M
    Whybra, C
    Kohlschütter, A
    Kampmann, C
    Beck, M
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2005, 28 (06) : 1011 - 1017
  • [4] Permanent transfemoral pacemaker implantation is the technique of choice for patients in whom the superior vena cava is inaccessible
    Barakat, K
    Hill, J
    Kelly, P
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2000, 23 (04): : 446 - 449
  • [5] BETREMIEUX P, 1985, ANN PEDIATR-PARIS, V32, P639
  • [6] Cardiovascular changes in mucopolysaccharidoses in Taiwan
    Chen, MR
    Lin, SP
    Hwang, HK
    Yu, CH
    [J]. ACTA CARDIOLOGICA, 2005, 60 (01) : 51 - 53
  • [7] Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders - clinical and echocardiographic findings in 64 patients
    Dangel, JH
    [J]. EUROPEAN JOURNAL OF PEDIATRICS, 1998, 157 (07) : 534 - 538
  • [8] Permanent transfemoral pacemaker implantation in a child with Maroteaux Lamy syndrome
    Dilber, E
    Çeliker, A
    Karagöz, T
    Kalkanoglu, HS
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2002, 25 (12): : 1784 - 1785
  • [9] PERMANENT PACEMAKER IMPLANTATION USING THE FEMORAL VEIN - A PRELIMINARY-REPORT
    ELLESTAD, MH
    CASO, R
    GREENBERG, PS
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 1980, 3 (04): : 418 - 424
  • [10] The natural course and the impact of therapies of cardiac involvement in the mucopolysaccharidoses
    Fesslova, Vlasta
    Corti, Paola
    Sersale, Giovanna
    Rovelli, Attilio
    Russo, Pierluigi
    Mannarino, Savina
    Butera, Gianfranco
    Parini, Rossella
    [J]. CARDIOLOGY IN THE YOUNG, 2009, 19 (02) : 170 - 178